A pressing issue affecting 1.1 million people in the US
HemoGenyx seeks to address the problems faced by tens of thousands of blood cancer patients that arise with Bone Marrow (BM) and Hematopoietic Stem Cell (HSC) Transplants, with their revolutionary treatments and therapies. Broad range of adverse side effects associated with current methods of conditioning patients for BM/HSC transplants – preventing many patients from receiving such treatment.
High failure rate of BM/HSC transplants
Transplants are carried out annually worldwide
Acute shortage of BM/HSC donors
A broad background in drug discovery and developing new drugs and navigating through the regulatory processOur pipeline
A rich academic history at the base of our groundbreaking work
A rich academic history at the base of our groundbreaking work The company’s team has a broad background in developing new drugs and moving through the regulatory process. The company has been granted FDA orphan drug designation for its lead cell therapy product, the Hu-PHECs, to treat aplastic anaemia, enabling a faster route to commercialization, to get the therapies and treatments to patients most in need. The Company is seeking to expand the application to other blood diseases.Find out more about us